Priority therapy areas are Pain and Inflammation, Dermatology, Gastroenterology, Ophthalmology, and Sleep Disorders. The product portfolio consists of several well-established products, such as Aldara (treatment of conditions such as Actinic Keratosis), Difflam (sore throat), Molaxole (constipation) and Lutein Omega 3 (AMD).
About 90% of total sales are generated by own products. The 10 largest products contribute to 50% of total sales, and the largest of these makes up about 15% of total sales.
Meda is increasingly focusing on specialised pharmaceuticals that target smaller patient groups. Specialist pharmaceuticals often mean lower sales overhead, because marketing can be directed toward a limited, clearly defined target group. The market for specialist drugs is generally less subject to competition and less price-sensitive, compared with a traditional focus on big sellers that require massive marketing efforts in an often highly competitive market.
Refer to each therapy area for a shorter presentation of several products in Meda's portfolio.